| |
|
|
|
| deaths (OS) |
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) |
|
| pembrolizumab alone vs. placebo | 1 | 0.54 [0.30; 0.97], 1 RCT, I2=0%
unassessable degree of certainty |
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1) |
|
| atezolizumab alone vs. sunitinib | 1 | - |
| atezolizumab plus bevacizumab vs. sunitinib | 2 | 0.93 [0.76; 1.14], 1 RCT, I2=0%
inconclusive result |
| avelumab plus axitinib vs. sunitinib | 1 | 0.80 [0.62; 1.03], 1 RCT, I2=0%
inconclusive result |
| nivolumab plus cabozantinib vs. sunitinib | 1 | 0.60 [0.40; 0.89], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
| nivolumab plus ipilimumab vs. sunitinib | 3 | 0.68 [0.49; 0.95], 1 RCT, I2=0%
unassessable degree of certainty |
| pembrolizumab plus axitinib vs. sunitinib | 1 | 0.53 [0.38; 0.74], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
| pembrolizumab plus lenvatinib vs. sunitinib | 1 | 0.66 [0.49; 0.88], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative |
|
| atezolizumab plus bevacizumab vs. sunitinib | 1 | - |
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive |
|
| atezolizumab alone vs. sunitinib | 1 | - |
| atezolizumab plus bevacizumab vs. sunitinib | 2 | 0.84 [0.62; 1.14], 1 RCT, I2=0%
inconclusive result |
| avelumab plus axitinib vs. sunitinib | 1 | 0.69 [0.58; 0.83], 1 RCT, I2=0%
unassessable degree of certainty |
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2) |
|
| atezolizumab plus cabozantinib vs. cabozantinib | 1 | 0.94 [0.70; 1.27], 1 RCT, I2=0%
inconclusive result |
|
| nivolumab alone vs. everolimus | 1 | 0.73 [0.57; 0.93], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
